NovoCure (NVCR) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

NVCR Stock Forecast


NovoCure stock forecast is as follows: an average price target of $68.92 (represents a 303.28% upside from NVCR’s last price of $17.09) and a rating consensus of 'Hold', based on 6 wall street analysts offering a 1-year stock forecast.

NVCR Price Target


The average price target for NovoCure (NVCR) is $68.92 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $200.00 to $14.50. This represents a potential 303.28% upside from NVCR's last price of $17.09.

NVCR Analyst Ratings


Hold

According to 6 Wall Street analysts, NovoCure's rating consensus is 'Hold'. The analyst rating breakdown for NVCR stock is 0 'Strong Buy' (0.00%), 2 'Buy' (33.33%), 3 'Hold' (50.00%), 1 'Sell' (16.67%), and 0 'Strong Sell' (0.00%).

NovoCure Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 16, 2024Emily BodnarH.C. Wainwright--68.73%75.54%
Jul 26, 2024Emily BodnarH.C. Wainwright--31.47%40.43%
May 03, 2024Emily BodnarH.C. Wainwright--55.04%28.73%
May 02, 2024Vijay KumarEvercore ISI---1.89%-15.16%
Apr 10, 2024Jason BednarPiper Sandler--88.17%63.84%
Apr 03, 2024Larry BiegelsenWells Fargo--191.87%145.76%
Mar 27, 2024H.C. Wainwright--63.93%40.43%
Jan 06, 2023J.P. Morgan---9.21%479.29%
Jan 06, 2023Wells Fargo---9.94%526.10%
Jan 05, 2023Emily BodnarH.C. Wainwright--30.31%719.19%
Row per page
Go to

The latest NovoCure stock forecast, released on Oct 16, 2024 by Emily Bodnar from H.C. Wainwright, set a price target of $30.00, which represents a 68.73% increase from the stock price at the time of the forecast ($17.78), and a 75.54% increase from NVCR last price ($17.09).

NovoCure Price Target by Period


1M3M12M
# Anlaysts-17
Avg Price Target-$30.00$26.36
Last Closing Price$17.09$17.09$17.09
Upside/Downside-100.00%75.54%54.24%

In the current month, the average price target of NovoCure stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NovoCure's last price of $17.09. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2024H.C. WainwrightBuyBuyHold
Oct 16, 2024H.C. WainwrightNeutralBuyUpgrade
Jul 26, 2024H.C. WainwrightNeutralNeutralHold
Jul 02, 2024Piper SandlerNeutralNeutralHold
Jul 02, 2024H.C. WainwrightUnderperformUnderperformHold
Jun 04, 2024Wells FargoNeutralNeutralHold
May 24, 2024Piper SandlerOverweightOverweightHold
May 03, 2024H.C. WainwrightNeutralNeutralHold
May 02, 2024Wells FargoBuyBuyHold
May 02, 2024Evercore ISINegativeNegativeHold
Row per page
Go to

NovoCure's last stock rating was published by H.C. Wainwright on Oct 31, 2024. The company gave NVCR a "Buy" rating, the same as its previous rate.

NovoCure Financial Forecast


NovoCure Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue---------$127.32M$126.05M$122.18M$128.43M$131.00M$140.87M$137.55M$133.21M$133.61M$133.52M$134.69M$143.95M$132.66M$115.92M$101.83M$99.23M$92.06M$86.71M$73.31M$52.13M$34.88M
Avg Forecast$162.05M$159.55M$156.85M$155.00M$153.04M$143.95M$135.83M$131.44M$133.80M$128.75M$124.25M$127.77M$128.40M$130.61M$134.97M$134.08M$133.00M$141.27M$141.50M$138.70M$144.00M$119.51M$105.70M$101.92M$99.20M$86.94M$78.98M$72.74M$44.66M$39.86M
High Forecast$165.62M$163.06M$160.30M$160.29M$155.89M$143.99M$135.83M$131.44M$133.85M$137.79M$126.99M$130.58M$131.23M$130.61M$134.97M$134.08M$133.00M$141.27M$141.50M$138.70M$144.00M$119.51M$105.70M$101.92M$99.20M$86.94M$78.98M$72.74M$53.59M$47.84M
Low Forecast$158.76M$156.31M$153.66M$149.52M$150.51M$143.90M$135.83M$131.44M$133.75M$123.39M$121.73M$125.17M$125.79M$130.61M$134.97M$134.08M$133.00M$141.27M$141.50M$138.70M$144.00M$119.51M$105.70M$101.92M$99.20M$86.94M$78.98M$72.74M$35.73M$31.89M
# Analysts11126311263344443333316811711771715
Surprise %---------0.99%1.01%0.96%1.00%1.00%1.04%1.03%1.00%0.95%0.94%0.97%1.00%1.11%1.10%1.00%1.00%1.06%1.10%1.01%1.17%0.88%

NovoCure's average Quarter revenue forecast for Dec 23 based on 2 analysts is $133.80M, with a low forecast of $133.75M, and a high forecast of $133.85M. NVCR's average Quarter revenue forecast represents a 5.09% increase compared to the company's last Quarter revenue of $127.32M (Sep 23).

NovoCure EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11126311263344443333316811711771715
EBITDA---------$-55.44M$-62.66M$-60.25M$-42.98M$-21.95M$-18.47M$1.80M$-22.91M$-7.80M$-10.76M$-364.00K$11.30M$13.23M$6.65M$-3.92M$875.00K$3.23M$2.09M$-6.56M$-15.33M$-14.16M
Avg Forecast$-13.04M$-12.84M$-12.62M$-12.47M$-12.31M$-11.58M$-10.93M$-2.66M$-10.76M$-10.36M$-10.00M$-2.41M$-13.86M$-14.03M$-14.50M$-2.58M$-14.29M$-15.18M$-15.20M$-1.31M$-15.47M$-12.84M$-11.36M$-4.32M$-10.66M$-9.34M$-8.49M$-7.03M$-12.76M$-15.93M
High Forecast$-12.77M$-12.58M$-12.36M$-12.03M$-12.11M$-11.58M$-10.93M$-2.12M$-10.76M$-9.93M$-9.79M$-1.93M$-11.09M$-14.03M$-14.50M$-2.07M$-14.29M$-15.18M$-15.20M$-1.05M$-15.47M$-12.84M$-11.36M$-3.45M$-10.66M$-9.34M$-8.49M$-5.62M$-10.21M$-12.74M
Low Forecast$-13.32M$-13.12M$-12.90M$-12.90M$-12.54M$-11.58M$-10.93M$-3.19M$-10.77M$-11.09M$-10.22M$-2.90M$-16.63M$-14.03M$-14.50M$-3.10M$-14.29M$-15.18M$-15.20M$-1.57M$-15.47M$-12.84M$-11.36M$-5.18M$-10.66M$-9.34M$-8.49M$-8.43M$-15.32M$-19.11M
Surprise %---------5.35%6.27%24.95%3.10%1.56%1.27%-0.70%1.60%0.51%0.71%0.28%-0.73%-1.03%-0.59%0.91%-0.08%-0.35%-0.25%0.93%1.20%0.89%

4 analysts predict NVCR's average Quarter EBITDA for Jun 22 to be $-14.50M, with a high of $-14.50M and a low of $-14.50M. This is -903.89% lower than NovoCure's previous annual EBITDA (Mar 22) of $1.80M.

NovoCure Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11126311263344443333316811711771715
Net Income---------$-49.48M$-57.42M$-53.06M$-37.30M$-26.58M$-24.01M$-4.65M$-26.46M$-13.12M$-14.64M$-4.13M$4.92M$9.28M$1.66M$3.95M$4.26M$1.93M$-1.27M$-12.15M$-20.72M$-18.05M
Avg Forecast$-44.38M$-40.77M$-41.13M$-41.49M$-38.35M$-36.13M$-43.61M$-7.65M$-56.44M$-56.83M$-54.12M$-6.95M$-16.01M$-28.16M$-15.62M$-7.44M$-11.04M$-7.95M$943.56K$-14.86M$13.52M$4.19M$-403.88K$4.35M$1.69M$-4.77M$-7.85M$-13.02M$-17.26M$-20.30M
High Forecast$-43.21M$-39.70M$-40.05M$-36.61M$-32.87M$-35.18M$-42.46M$-6.12M$-50.05M$-46.99M$-52.69M$-5.56M$-12.81M$-28.16M$-15.62M$-5.95M$-11.04M$-7.95M$943.56K$-11.89M$13.52M$4.19M$-403.88K$5.22M$1.69M$-4.77M$-7.85M$-10.41M$-13.81M$-16.24M
Low Forecast$-45.65M$-41.94M$-42.31M$-50.04M$-44.93M$-37.17M$-44.86M$-9.18M$-64.96M$-62.29M$-55.67M$-8.34M$-19.21M$-28.16M$-15.62M$-8.92M$-11.04M$-7.95M$943.56K$-17.83M$13.52M$4.19M$-403.88K$3.48M$1.69M$-4.77M$-7.85M$-15.62M$-20.71M$-24.36M
Surprise %---------0.87%1.06%7.63%2.33%0.94%1.54%0.63%2.40%1.65%-15.52%0.28%0.36%2.22%-4.10%0.91%2.52%-0.40%0.16%0.93%1.20%0.89%

NovoCure's average Quarter net income forecast for Mar 21 is $-14.86M, with a range of $-17.83M to $-11.89M. NVCR's average Quarter net income forecast represents a -402.23% decrease compared to the company's last Quarter net income of $4.92M (Dec 20).

NovoCure SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11126311263344443333316811711771715
SG&A---------$99.85M$99.27M$93.11M$87.70M$73.90M$76.42M$68.39M$69.99M$63.81M$66.90M$62.48M$59.72M$56.42M$53.87M$55.44M$50.55M$46.54M$44.96M$42.57M$35.46M$27.18M
Avg Forecast$91.09M$89.69M$88.17M$87.13M$86.03M$80.91M$76.35M$112.55M$75.21M$72.37M$69.84M$102.31M$42.35M$73.42M$75.87M$109.43M$74.76M$79.41M$79.54M$77.97M$80.94M$67.18M$59.41M$60.99M$55.76M$48.87M$44.40M$45.61M$29.53M$30.58M
High Forecast$93.10M$91.66M$90.11M$90.10M$87.63M$80.94M$76.35M$135.06M$75.24M$77.45M$71.38M$122.78M$50.81M$73.42M$75.87M$131.31M$74.76M$79.41M$79.54M$77.97M$80.94M$67.18M$59.41M$73.18M$55.76M$48.87M$44.40M$54.73M$35.44M$36.69M
Low Forecast$89.24M$87.86M$86.38M$84.05M$84.61M$80.89M$76.35M$90.04M$75.18M$69.36M$68.42M$81.85M$33.88M$73.42M$75.87M$87.54M$74.76M$79.41M$79.54M$77.97M$80.94M$67.18M$59.41M$48.79M$55.76M$48.87M$44.40M$36.49M$23.62M$24.46M
Surprise %---------1.38%1.42%0.91%2.07%1.01%1.01%0.63%0.94%0.80%0.84%0.80%0.74%0.84%0.91%0.91%0.91%0.95%1.01%0.93%1.20%0.89%

NovoCure's average Quarter SG&A projection for Dec 23 is $75.21M, based on 2 Wall Street analysts, with a range of $75.18M to $75.24M. The forecast indicates a -24.68% fall compared to NVCR last annual SG&A of $99.85M (Sep 23).

NovoCure EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11126311263344443333316811711771715
EPS---------$-0.46$-0.54$-0.50$-0.36$-0.25$-0.23$-0.04$-0.25$-0.13$-0.14$-0.04$0.05$0.09$0.02$0.04$0.04$0.02$-0.01$-0.13$-0.23$-0.21
Avg Forecast$-0.41$-0.38$-0.38$-0.38$-0.35$-0.33$-0.40$-0.42$-0.52$-0.53$-0.50$-0.32$-0.30$-0.26$-0.14$-0.18$-0.10$-0.07$0.01$0.01$0.13$0.04$-0.00$0.03$0.02$-0.04$-0.07$-0.14$-0.11$-0.27
High Forecast$-0.40$-0.37$-0.37$-0.34$-0.30$-0.32$-0.39$-0.41$-0.46$-0.43$-0.49$-0.31$-0.29$-0.26$-0.14$-0.18$-0.10$-0.07$0.01$0.01$0.13$0.04$-0.00$0.03$0.02$-0.04$-0.07$-0.14$-0.09$-0.22
Low Forecast$-0.42$-0.39$-0.39$-0.46$-0.42$-0.34$-0.41$-0.43$-0.60$-0.58$-0.51$-0.33$-0.31$-0.26$-0.14$-0.18$-0.10$-0.07$0.01$0.01$0.13$0.04$-0.00$0.03$0.02$-0.04$-0.07$-0.14$-0.13$-0.32
Surprise %---------0.88%1.08%1.55%1.19%0.96%1.59%0.24%2.44%1.76%-15.98%-2.67%0.40%2.31%-5.33%1.17%2.55%-0.45%0.14%0.91%2.09%0.78%

According to 3 Wall Street analysts, NovoCure's projected average Quarter EPS for Mar 21 is $0.01, with a low estimate of $0.01 and a high estimate of $0.01. This represents a -70.00% decrease compared to NVCR previous annual EPS of $0.05 (Dec 20).

NovoCure Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
NVCRNovoCure--303.28%Hold
IRTCiRhythm--63.96%Buy
TMDXTransMedics Group--59.76%Buy
INMDInMode--48.73%Hold
LIVNLivaNova--36.36%Buy
CNMDCONMED--33.87%Buy
NARIInari Medical--32.88%Buy
INSPInspire Medical Systems--28.66%Buy
PODDInsulet--4.58%Buy
ITGRInteger--1.56%Buy
MASIMasimo---4.31%Buy
GMEDGlobus Medical---6.32%Buy
PENPenumbra---6.50%Buy
SWAVShockWave Medical---22.88%Hold

NVCR Forecast FAQ


Is NovoCure a good buy?

No, according to 6 Wall Street analysts, NovoCure (NVCR) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 33.33% of NVCR's total ratings.

What is NVCR's price target?

NovoCure (NVCR) average price target is $68.92 with a range of $14.5 to $200, implying a 303.28% from its last price of $17.09. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will NovoCure stock go up soon?

According to Wall Street analysts' prediction for NVCR stock, the company can go up by 303.28% (from the last price of $17.09 to the average price target of $68.92), up by 1070.28% based on the highest stock price target, and down by -15.16% based on the lowest stock price target.

Can NovoCure stock reach $30?

NVCR's average twelve months analyst stock price target of $68.92 supports the claim that NovoCure can reach $30 in the near future.

What are NovoCure's analysts' financial forecasts?

NovoCure's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $564.26M (high $567.15M, low $561.69M), average EBITDA is $-37.478M (high $-36.74M, low $-38.242M), average net income is $-126M (high $-117M, low $-136M), average SG&A $355.84M (high $379.98M, low $331.88M), and average EPS is $-1.511 (high $-1.43, low $-1.605). NVCR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $633.45M (high $649.28M, low $618.25M), average EBITDA is $-50.964M (high $-49.741M, low $-52.237M), average net income is $-168M (high $-160M, low $-180M), average SG&A $356.07M (high $364.97M, low $347.53M), and average EPS is $-1.55 (high $-1.474, low $-1.662).

Did the NVCR's actual financial results beat the analysts' financial forecasts?

Based on NovoCure's last annual report (Dec 2022), the company's revenue was $537.84M, beating the average analysts forecast of $528.05M by 1.85%. Apple's EBITDA was $-89.523M, beating the average prediction of $-44.977M by 99.04%. The company's net income was $-92.534M, beating the average estimation of $-67.215M by 37.67%. Apple's SG&A was $306.41M, beating the average forecast of $301.06M by 1.78%. Lastly, the company's EPS was $-0.88, missing the average prediction of $-0.894 by -1.56%. In terms of the last quarterly report (Sep 2023), NovoCure's revenue was $127.32M, missing the average analysts' forecast of $128.75M by -1.11%. The company's EBITDA was $-55.442M, beating the average prediction of $-10.358M by 435.23%. NovoCure's net income was $-49.485M, missing the average estimation of $-56.83M by -12.92%. The company's SG&A was $99.85M, beating the average forecast of $72.37M by 37.97%. Lastly, the company's EPS was $-0.46, missing the average prediction of $-0.525 by -12.38%